Release Date: October 31, 2023
Expiration Date: October 31, 2024
Activity Overview
SimulatEd™ is an online, on-demand activity that promotes clinical reasoning and updates clinicians on the latest advances that impact patient care. Learners are provided with simulated patient encounters that provide insight into the patient journey along the continuum of care. Learners are asked to make clinical decisions as the cases progress. This allows them to employ critical thinking and decision-making in a consequence-free environment; it also leverages cohort learning as participants compare their treatment choices with those of peers and experts. This activity focuses on 3 people with type 2 diabetes (T2D), each with their own priorities and needs relating to the management of their disease.
Target Audience
This educational activity is directed toward primary care physicians, nurse practitioners, and physician assistants. Other clinicians involved in the management of patients with diabetes will be invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Utilize appropriate guideline recommendations in selecting pharmacotherapy for patients with T2D who may benefit from intensified therapies to achieve glycemic and weight loss goals
- Assess the efficacy and safety of current therapies for the management of T2D and obesity
- Integrate patient-centered strategies in formulating treatment plans that incorporate patient-centered strategies and shared goals of therapy for patients with T2D who would benefit from intensified therapy

Juan Pablo Frias, M.D.
Medical Director and Principal Investigator
Velocity Clinical Research
Los Angeles, California
Disclosures: Research Support: Akero, Altimmune, Boehringer Ingelheim, 89bio, Eli Lilly, Intercept, IONIS, Janssen, Madrigal, Merck, NorthSea Therapeutics, Novartis, Novo Nordisk, Oramed, Pfizer, Sanofi, Shionogi. Advisory Boards and Consulting: Akero, Altimmune, Biomea Fusion, Boehringer Ingelheim, Carmot Therapeutics, Echosens, 89bio, Eli Lilly, Gilead, Intercept, Metacrine, Merck, Novo Nordisk, Pfizer, Sanofi. Speaker Bureau: Eli Lilly.
Jessica Hansen, MD
Internal Medicine
University of California San Diego
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here